Factors associated with bisphosphonate treatment failure in postmenopausal women with primary osteoporosis

Osteoporosis International

Volumn 25, Issue 4, 2014, Pages 1401-1410

  Cairoli, E ^a   Eller Vainicher, C ^a   Ulivieri, F M ^a   Zhukouskaya, V V ^a   Palmieri, S ^a   Morelli, V ^a   Beck Peccoz, P ^a   Chiodini, I ^a  

^a UNIVERSITY OF MILAN   (Italy)

Author keywords

Alkaline phosphatase; Bisphosphonates; Primary osteoporosis; Treatment failure

Indexed keywords

25 HYDROXYVITAMIN D; ALBUMIN; ALENDRONIC ACID; ALKALINE PHOSPHATASE; CITRATE CALCIUM; COLECALCIFEROL; RISEDRONIC ACID; BIOLOGICAL MARKER; BISPHOSPHONIC ACID DERIVATIVE; BONE DENSITY CONSERVATION AGENT; ETIDRONIC ACID;

ARTICLE; BONE DENSITY; CALCIUM INTAKE; CLINICAL EVALUATION; DUAL ENERGY X RAY ABSORPTIOMETRY; FEMALE; FEMUR NECK; FOLLOW UP; FRAGILITY FRACTURE; HUMAN; LABORATORY TEST; LUMBAR SPINE; MAJOR CLINICAL STUDY; POSTMENOPAUSE; PRIMARY OSTEOPOROSIS; PRIORITY JOURNAL; SPINE FRACTURE; SPINE MALFORMATION; SPINE RADIOGRAPHY; TREATMENT FAILURE; VITAMIN SUPPLEMENTATION; AGED; ANALOGS AND DERIVATIVES; BLOOD; BONE REMODELING; DRUG EFFECTS; HIP; LUMBAR VERTEBRA; MEDICATION COMPLIANCE; MIDDLE AGED; OSTEOPOROSIS, POSTMENOPAUSAL; OSTEOPOROTIC FRACTURES; PATHOPHYSIOLOGY; PHOTON ABSORPTIOMETRY; PHYSIOLOGY; PROCEDURES; RISK FACTOR; SMOKING; VERY ELDERLY;

ABSORPTIOMETRY, PHOTON; AGED; AGED, 80 AND OVER; ALENDRONATE; ALKALINE PHOSPHATASE; BIOLOGICAL MARKERS; BONE DENSITY; BONE DENSITY CONSERVATION AGENTS; BONE REMODELING; DIPHOSPHONATES; ETIDRONIC ACID; FEMALE; FEMUR NECK; FOLLOW-UP STUDIES; HIP JOINT; HUMANS; LUMBAR VERTEBRAE; MEDICATION ADHERENCE; MIDDLE AGED; OSTEOPOROSIS, POSTMENOPAUSAL; OSTEOPOROTIC FRACTURES; RISK FACTORS; SMOKING; TREATMENT FAILURE;

EID: 84897028714     PISSN: 0937941X     EISSN: 14332965     Source Type: Journal    
DOI: 10.1007/s00198-014-2619-3     Document Type: Article

References (39)

1. Lewiecki EM, Watts NB (2008) Assessing response to osteoporosis therapy. Osteoporos Int 19(10):1363-1368
2. Lewiecki EM (2003) Nonresponders to osteoporosis therapy. J Clin Densitom 6(4):307-314
3. del Puente A, Scognamiglio A, Itto E, Ferrara G, Oriente P (2000) Intramuscular clodronate in nonresponders to oral alendronate therapy for osteoporosis. J Rheumatol 27(8):1980-1983 (Pubitemid 30670491)
4. Heckman GA, Papaioannou A, Sebaldt RJ, Ioannidis G, Petrie A, Goldsmith C, Adachi JD (2002) Effect of vitamin D on bone mineral density of elderly patients with osteoporosis responding poorly to bisphosphonates. BMC Musculoskelet Disord 3:6
5. Sawka AM, Adachi JD, Ioannidis G, Olszynski WP, Brown JP, Hanley DA, Murray T, Josse R, Sebaldt RJ, Petrie A, Tenenhouse A, Papaioannou A, Goldsmith CH (2003) What predicts early fracture or bone loss on bisphosphonate therapy? J Clin Densitom 6(4):315-322 (Pubitemid 38114507)
6. Adami S, Isaia G, Luisetto G, Minisola S, Sinigaglia L, Gentilella R, Agnusdei D, Iori N, Nuti R, ICARO Study Group (2006) Fracture incidence and characterization in patients on osteoporosis treatment: the ICARO study. J Bone Miner Res 21(10):1565-1570 (Pubitemid 44484601)
7. Adami S, Isaia G, Luisetto G, Minisola S, Sinigaglia L, Silvestri S, Agnusdei D, Gentilella R, Nuti R, ICARO Study Group (2008) Osteoporosis treatment and fracture incidence: the ICARO longitudinal study. Osteoporos Int 19(8):1219-1223
8. Peris P, Martínez-Ferrer A, Monegal A, Martínez de Osaba MJ, Muxi A, Guañabens N (2012) 25 hydroxyvitamin D serum levels influence adequate response to bisphosphonate treatment in postmenopausal osteoporosis. Bone 51(1):54-58
9. Díez-Pérez A, Olmos JM, Nogués X, Sosa M, Díaz-Curiel M, Pérez-Castrillón JL, Pérez-Cano R, Muñoz-Torres M, Torrijos A, Jodar E, Del Rio L, Caeiro-Rey JR, Farrerons J, Vila J, Arnaud C, González-Macías J (2012) Risk factors for prediction of inadequate response to antiresorptives. J Bone Miner Res 27(4):817-824
10. Carmel AS, Shieh A, Bang H, Bockman RS (2012) The 25(OH)D level needed to maintain a favorable bisphosphonate response is ≥33 ng/ml. Osteoporos Int 23(10):2479-2487
11. Prieto-Alhambra D, Pagès-Castellà A, Wallace G, Javaid M, Judge A, Nogués X, Arden N, Cooper C, Diez-Perez A (2013) Predictors of fracture while on treatment with oral bisphosphonates: a population-based cohort study. J Bone Miner Res. doi:10.1002/jbmr.2011
12. Sebba AI (2008) Significance of a decline in bone mineral density while receiving oral bisphosphonate treatment. Clin Ther 30(3):443-52
13. Jakob F, Marín F, Martín-Mola E, Torgerson D, Fardellone P, Adami S, Thalassinos NC, Sykes D, Melo-Gomes J, Chinn C, Nicholson T, Cooper C (2006) Characterization of patients with an inadequate clinical outcome from osteoporosis therapy: the Observational Study of Severe Osteoporosis (OSSO). QJM 99(8):531-543 (Pubitemid 44304838)
14. Díez-Pérez A, González-Macías J (2008) Inadequate responders to osteoporosis treatment: proposal for an operational definition. Osteoporos Int 19(11):1511-1516
15. Diez-Perez A, Adachi JD, Agnusdei D, Bilezikian JP, Compston JE, Cummings SR, Eastell R, Eriksen EF, Gonzalez-Macias J, Liberman UA, Wahl DA, Seeman E, Kanis JA, Cooper C (2012) IOF CSA Inadequate Responders Working Group. Treatment failure in osteoporosis. Osteoporos Int 23(12):2769-2774
16. Garnero P, Darte C, Delmas PD (1999) A model to monitor the efficacy of alendronate treatment in women with osteoporosis using a biochemical marker of bone turnover. Bone 24(6):603-609 (Pubitemid 29234074)
17. Delmas PD (2000) Markers of bone turnover for monitoring treatment of osteoporosis with antiresorptive drugs. Osteoporos Int 11(Suppl 6):S66-S76
18. Fitzpatrick LA (2002) Secondary causes of osteoporosis. Mayo Clin Proc 77(5):453-468
19. Black DM, Cummings SR, Karpf DB, Cauley JA, Thompson DE, Nevitt MC, Bauer DC, Genant HK, Haskell WL, Marcus R, Ott SM, Torner JC, Quandt SA, Reiss TF, Ensrud KE (1996) Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet 348(9041):1535-1541 (Pubitemid 26411651)
20. Harris ST, Watts NB, Genant HK, McKeever CD, Hangartner T, Keller M, Chesnut CH 3rd, Brown J, Eriksen EF, Hoseyni MS, Axelrod DW, Miller PD (1999) Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group. JAMA 282(14):1344-1352 (Pubitemid 29483192)
21. Huybrechts KF, Ishak KJ, Caro JJ (2006) Assessment of compliance with osteoporosis treatment and its consequences in a managed care population. Bone 38(6):922-928 (Pubitemid 44498580)
22. Eller-Vainicher C, Cairoli E, Zhukouskaya VV, Morelli V, Palmieri S, Scillitani A, Beck-Peccoz P, Chiodini I (2013) Prevalence of subclinical contributors to low bone mineral density and/or fragility fracture. Eur J Endocrinol 169(2):225-237
23. Kanis JA, Johnell O, Oden A, Johansson H, McCloskey E (2008) FRAX and the assessment of fracture probability in men and women from the UK. Osteoporos Int 19(4):385-397
24. Adami S, Romagnoli E, Carnevale V, Scillitani A, Giusti A, Rossini M, Gatti D, Nuti R, Minisola S (2011) Guidelines on prevention and treatment of vitamin D deficiency. Reumatismo 63(3):129-147
25. Adami S, Bertoldo F, Brandi ML, Cepollaro C, Filipponi P, Fiore E, Frediani B, Giannini S, Gonnelli S, Isaia GC, Luisetto G, Mannarino E, Marcocci C, Masi L, Mereu C, Migliaccio S, Minisola S, Nuti R, Rini G, Rossini M, Varenna M, Ventura L, Bianchi G, Società Italiana dell'Osteoporosi, del Metabolismo Minerale e delle Malattie dello Scheletro (2009) Guidelines for the diagnosis, prevention and treatment of osteoporosis. Reumatismo 61(4):260-284
26. Varenna M, Binelli L, Zucchi F, Ghiringhelli D, Sinigaglia L (2001) Unbalanced diet to lower serum cholesterol level is a risk factor for postmenopausal osteoporosis and distal forearm fracture. Osteoporos Int 12(4):296-301 (Pubitemid 34912736)
27. Husten CG (2009) How should we define light or intermittent smoking? Does it matter? Nicotine Tob Res 11(2):111-121
28. Genant HK, Wu CY, van Kuijk C, Nevitt MC (1993) Vertebral fracture assessment using a semiquantitative technique. J Bone Miner Res 8(9):1137-1148 (Pubitemid 23261108)
29. Crans GG, Genant HK, Krege JH (2005) Prognostic utility of a semiquantitative spinal deformity index. Bone 37(2):175-179 (Pubitemid 40962424)
30. Kanis JA (2002) Diagnosis of osteoporosis and assessment of fracture risk. Lancet 359(9321):1929-1936
31. Kanis JA, Johnell O, Oden A, Johansson H, De Laet C, Eisman JA, Fujiwara S, Kroger H, McCloskey EV, Mellstrom D, Melton LJ, Pols H, Reeve J, Silman A, Tenenhouse A (2005) Smoking and fracture risk: a meta-analysis. Osteoporos Int 16(2):155-162 (Pubitemid 40193202)
32. Cornuz J, Feskanich D, Willett WC, Colditz GA (1999) Smoking, smoking cessation, and risk of hip fracture in women. Am J Med 106(3):311-314 (Pubitemid 29153409)
33. Yan C, Avadhani NG, Iqbal J (2011) The effects of smoke carcinogens on bone. Curr Osteoporos Rep 9(4):202-209
34. Yoon V, Maalouf NM, Sakhaee K (2012) The effects of smoking on bone metabolism. Osteoporos Int 23(8):2081-2092
35. Bauer DC, Garnero P, Hochberg MC, Santora A, Delmas P, Ewing SK, Black DM (2006) Fracture Intervention Research Group. Pretreatment levels of bone turnover and the antifracture efficacy of alendronate: the fracture intervention trial. J Bone Miner Res 21(2):292-299 (Pubitemid 43265295)
36. Schousboe JT, Bauer DC, Nyman JA, Kane RL, Melton LJ, Ensrud KE (2007) Potential for bone turnover markers to cost-effectively identify and select post-menopausal osteopenic women at high risk of fracture for bisphosphonate therapy. Osteoporos Int 18(2):201-210 (Pubitemid 46090224)
37. Seibel MJ, Naganathan V, Barton I, Grauer A (2004) Relationship between pretreatment bone resorption and vertebral fracture incidence in postmenopausal osteoporotic women treated with risedronate. J Bone Miner Res 19(2):323-329 (Pubitemid 38116747)
38. Seibel MJ (2006) Biochemical markers of bone turnover part II: clinical applications in the management of osteoporosis. Clin Biochem Rev 27(3):123
39. Vasikaran S, Eastell R, Bruyère O, Foldes AJ, Garnero P, Griesmacher A, McClung M, Morris HA, Silverman S, Trenti T, Wahl DA, Cooper C, Kanis JA (2011) IOF-IFCC Bone Marker Standards Working Group. Markers of bone turnover for the prediction of fracture risk and monitoring of osteoporosis treatment: a need for international reference standards. Osteoporos Int 22(2):391-420